key: cord-0892938-n8782dh0 authors: Anand, Sai Priya; Prévost, Jérémie; Nayrac, Manon; Beaudoin-Bussières, Guillaume; Benlarbi, Mehdi; Gasser, Romain; Brassard, Nathalie; Laumaea, Annemarie; Gong, Shang Yu; Bourassa, Catherine; Brunet-Ratnasingham, Elsa; Medjahed, Halima; Gendron-Lepage, Gabrielle; Goyette, Guillaume; Gokool, Laurie; Morrisseau, Chantal; Bégin, Philippe; Martel-Laferrière, Valérie; Tremblay, Cécile; Richard, Jonathan; Bazin, Renée; Duerr, Ralf; Kaufmann, Daniel E.; Finzi, Andrés title: Longitudinal analysis of humoral immunity against SARS-CoV-2 Spike in convalescent individuals up to 8 months post-symptom onset date: 2021-01-25 journal: bioRxiv DOI: 10.1101/2021.01.25.428097 sha: 177dafebe4b983b05ac86c541314a9e6b9f1ee3d doc_id: 892938 cord_uid: n8782dh0 Functional and lasting immune responses to the novel coronavirus (SARS-CoV-2) are currently under intense investigation as antibody titers in plasma have been shown to decline during convalescence. Since the absence of antibodies does not equate to absence of immune memory, we sought to determine the presence of SARS-CoV-2-specific memory B cells in COVID-19 convalescent patients. In this study, we report on the evolution of the overall humoral immune responses on 101 blood samples obtained from 32 COVID-19 convalescent patients between 16 and 233 days post-symptom onset. Our observations indicate that anti-Spike and anti-RBD IgM in plasma decay rapidly, whereas the reduction of IgG is less prominent. Neutralizing activity in convalescent plasma declines rapidly compared to Fc-effector functions. Concomitantly, the frequencies of RBD-specific IgM+ B cells wane significantly when compared to RBD-specific IgG+ B cells, which increase over time, and the number of IgG+ memory B cells which remain stable thereafter for up to 8 months after symptoms onset. With the recent approval of highly effective vaccines for COVID-19, data on the persistence of immune responses are of central importance. Even though overall circulating SARS-CoV-2 Spike-specific antibodies contract over time during convalescence, we demonstrate that RBD-specific B cells increase and persist up to 8 months post symptom onset. We also observe modest increases in RBD-specific IgG+ memory B cells and importantly, detectable IgG and sustained Fc-effector activity in plasma over the 8-month period. Our results add to the current understanding of immune memory following SARS-CoV-2 infection, which is critical for the prevention of secondary infections, vaccine efficacy and herd immunity against COVID-19. A better understanding of the type and longevity of immune responses following viral infections 203 are critical to reveal immune mechanisms involved in protection from re-infection and protection 204 by vaccination. Data regarding these important issues continues to be gathered for SARS-CoV-205 2. In this study, we have contributed to the current understanding by reporting on the evolution of 206 the overall humoral immune responses in 101 blood samples obtained from 32 convalescent patients between 16 and 233 days PSO. Overall, we observed that IgM levels and 208 the neutralizing capacity of plasma decreases rapidly, whereas IgG and Fc-effector activity are 209 more sustained ( Figure 6 ). The antibody kinetics we observed herein are typical of those seen for 210 other human coronavirus infections, with antibodies peaking 2-4 weeks PSO followed by a 211 contraction phase (33). Furthermore, we show that COVID-19 patients generate RBD-specific 212 memory B cells and IgG+ B memory cells that persist for over 8 months. Similarly, recent studies 213 on the durability of SARS-CoV-2 immune responses have shown that although antibody levels 214 decrease, Spike-specific IgG+ memory B cell responses are generated and maintained (1, 5, 6) . 215 Additionally, studies demonstrated enhanced cellular immunity that protects non-human primates 216 from SARS-CoV-2 reinfection in the context of waning neutralizing antibodies (8). Thus, the 217 decline of antibody levels does not negate the protective potential because of the importance of 218 cellular responses against SARS-CoV-2 infection. This understanding is corroborated with a 219 recent risk assessment carried out in a cohort of 43,000 convalescent individuals demonstrating 220 that immunity elicited upon natural SARS-CoV-2 infection protects against reinfection with an 221 efficacy of >90% for at least 7 months (34). 222 223 Fc-mediated effector activity of antibodies has been recently shown to correlate with reduced 224 disease severity and mortality (21). Antibodies capable of mediating Fc-dependant functions, 225 such as antibody-dependent phagocytosis and ADCC, have been isolated from convalescent 226 donors (35). Importantly, Fc-mediated effector activity was shown to protect from SARS-CoV-2 227 infection in adapted mice and hamster models (9, 19, 32) . Thus, our observations of the 228 persistence of ADCC responses in convalescent plasma up to 8 months PSO suggest that Fc-229 mediated effector functions could play a vital role in protection from reinfection. Nevertheless, the 230 heterogeneity of immune responses between individuals is and will be an important factor when 231 evaluating the efficacy of immune responses upon re-exposure to SARS-CoV-2. 232 233 A recent study comparing humoral immunity generated by mRNA vaccinees (mRNA-1273 or 234 BNT162b2) and individuals recovered from natural infection observed similarities in antibody 235 binding titers and plasma neutralization capacity (36). Furthermore, this study also observed 236 similar frequencies of RBD-specific memory B cells between vaccinees and infected individuals. 237 Therefore, our results on the persistence of RBD-specific memory B cells up to 8 months after 238 natural infection is reassuring with regards to long-term vaccine efficacy. 239 All work was conducted in accordance with the Declaration of Helsinki in terms of informed 242 consent and approval by an appropriate institutional board. Convalescent plasmas were obtained 243 from donors who consented to participate in this research project at CHUM (19.381 Plasma from SARS-CoV-2-infected and pre-pandemic uninfected donors were collected, heat-249 inactivated for 1h at 56°C and stored at -80°C until ready to use in subsequent experiments. 250 Plasma from uninfected donors were used as negative controls and used to calculate the 251 seropositivity threshold in our ELISA, cell-based ELISA, and flow cytometry assays. The RBD-252 specific monoclonal antibody CR3022 was used as a positive control in our ELISAs, cell-based 253 ELISAs, and flow cytometry assays and was previously described (14, 16, 22 FreeStyle 293F cells (Invitrogen) were grown in FreeStyle 293F medium (Invitrogen) to a density 278 of 1 x 10 6 cells/mL at 37°C with 8% CO2 with regular agitation (150 rpm). Cells were transfected 279 with a plasmid coding for SARS-CoV-2 S RBD using ExpiFectamine 293 transfection reagent, as 280 directed by the manufacturer (Invitrogen). One week later, cells were pelleted and discarded. 281 Supernatants were filtered using a 0.22 µm filter (Thermo Fisher Scientific). The recombinant 282 RBD proteins were purified by nickel affinity columns, as directed by the manufacturer 283 (Invitrogen). The RBD preparations were dialyzed against phosphate-buffered saline (PBS) and 284 stored in aliquots at -80°C until further use. To assess purity, recombinant proteins were loaded 285 on SDS-PAGE gels and stained with Coomassie Blue. 286 287 The SARS-CoV-2 RBD ELISA assay used was recently described (16). Briefly, recombinant 289 SARS-CoV-2 S RBD proteins (2.5 μg/ml), or bovine serum albumin (BSA) (2.5 μg/ml) as a 290 negative control, were prepared in PBS and adsorbed to plates (MaxiSorp Nunc) overnight at 291 4°C. Coated wells were subsequently blocked with blocking buffer (Tris-buffered saline [TBS] 292 containing 0.1% Tween20 and 2% BSA) for 1h at room temperature. Wells were then washed 293 four times with washing buffer (Tris-buffered saline [TBS] containing 0.1% Tween20). CR3022 294 mAb (50ng/ml) or a 1/250 dilution of plasma from SARS-CoV-2-infected or uninfected donors 295 were prepared in a diluted solution of blocking buffer (0.1 % BSA) and incubated with the RBD-296 coated wells for 90 minutes at room temperature. Plates were washed four times with washing 297 buffer followed by incubation with secondary Abs (diluted in blocking buffer,0.4% BSA) for 1h at 298 room temperature, followed by four washes. HRP enzyme activity was determined after the 299 addition of a 1:1 mix of Western Lightning oxidizing and luminol reagents (Perkin Elmer Life 300 Technologies). Signal obtained with BSA was subtracted for each plasma and was then 302 normalized to the signal obtained with CR3022 mAb present in each plate. The seropositivity 303 threshold was established using the following formula: mean of all COVID-19 negative plasma + 304 (3 standard deviation of the mean of all COVID-19 negative plasma). Overnight rested PBMCs were stained with another cellular marker (cell proliferation dye 340 eFluor450; Thermo Fisher Scientific) and used as effector cells. Stained target and effector cells 341 were mixed at a ratio of 1:10 in 96-well V-bottom plates. Plasma from COVID+ or COVID-342 individuals (1/500 dilution) or monoclonal antibody CR3022 (1 µg/mL) were added to the 343 appropriate wells. The plates were subsequently centrifuged for 1 min at 300xg, and incubated at 344 37°C, 5% CO2 for 5 hours before being fixed in a 2% PBS-formaldehyde solution. ADCC activity 345 was calculated using the formula: [(% of GFP+ cells in Targets Fisher Scientific). The neutralization half-maximal inhibitory dilution (ID50) represents the plasma 367 dilution to inhibit 50% of the infection of 293T-ACE2 cells by SARS-CoV-2 pseudoviruses. 368 To detect SARS-CoV-2-specific B cells, we conjugated recombinant RBD proteins with Alexa 371 Fluor 488 or Alexa Fluor 594 (Thermo Fisher Scientific) according to the manufacturer's protocol. 372 Approximately 10 x 10 6 frozen PBMC from 13 convalescent donors were prepared in Falcon® Staining was performed at 4°C for 30min and cells were fixed using 2% paraformaldehyde at 4°C 387 for 15min. Stained PBMC samples were acquired on Symphony cytometer (BD Biosciences) and 388 analyzed using FlowJo v10.7.1 (TreeStar). In each experiment, PBMC from unexposed donors 389 (total of n=9) were included to ensure consistent specificity of the assay. Error bars indicate means ± SEM. Statistical significance was tested using repeated measures one-way ANOVA with a Holm-Sidak post-test (* P < 0.05; ** P < 0.01; *** P < 0.001; **** P < 0.0001). ELISA_RBD ( Correlograms were generated by plotting together all serological, immunological and demographic data obtained from convalescent patients. Circles are color-coded and sized according to the magnitude of the correlation coefficient (r). Red circles represent positive correlations between two variables and blue circles represent negative correlations. Asterisks indicate statistically significant correlations (*P < 0.05, **P < 0.01, ***P < 0.005). Correlation analysis was done using Spearman correlation rank tests. Parameters are clustered hierarchically according to the first principal component (FPC). Black surrounding boxes indicate adjusted p-values < 0.05 using Benjamini-Hochberg multiplicity correction. Legend: Cb-ELISA = cell-based ELISA, Neut = Neutralization, mem = memory, PSO = post-symptom onset, Sex = Female. CoV-2 assessed for up to 8 months after infection Cell Responses to SARS-CoV-2 Coronavirus in Humans with COVID-19 Disease and 578 Unexposed Individuals Sette 582 A, Crotty S. 2020. Antigen-Specific Adaptive Immunity to SARS-CoV-2 in Acute COVID-583 19 and Associations with Age and Disease Severity Rapid generation of 586 durable B cell memory to SARS-CoV-2 spike and nucleocapsid proteins in COVID-19 and 587 convalescence 2020. 591 Evolution of immunity to SARS-CoV-2 Evolution 599 of antibody immunity to SARS-CoV-2 SARS-CoV-2 infection protects 607 against rechallenge in rhesus macaques 2020. 612 Correlates of protection against SARS-CoV-2 in rhesus macaques Ultrapotent human antibodies protect against SARS-CoV-2 challenge 621 via multiple mechanisms REGN-COV2 antibodies prevent and 627 treat SARS-CoV-2 infection in rhesus macaques and hamsters Yancopoulos 632 GD, Trial I. 2020. REGN-COV2, a Neutralizing Antibody Cocktail, in Outpatients with 633 Covid-19 Structure, Function, 635 and Antigenicity of the SARS-CoV-2 Spike Glycoprotein Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven 639 Decline 643 of Humoral Responses against SARS-CoV-2 Spike in Convalescent Individuals Waning of SARS-CoV-2 RBD antibodies in longitudinal 647 convalescent plasma samples within four months after symptom onset Cross-sectional evaluation 654 of humoral responses against SARS-CoV-2 Spike Convergent antibody responses to SARS-CoV-2 in 663 convalescent individuals Antibodies in Persons with Mild Covid-19 The Fc-mediated effector functions of a potent 672 SARS-CoV-2 neutralizing antibody, SC31, isolated from an early convalescent COVID-19 673 patient, are essential for the optimal therapeutic efficacy of the antibody Asymptomatic and 678 symptomatic SARS-CoV-2 infections elicit polyfunctional antibodies Compromised Humoral Functional Evolution Tracks 683 with SARS-CoV-2 Mortality High-throughput detection of antibodies targeting the SARS-686 CoV-2 Spike in longitudinal convalescent plasma samples Studies in humanized mice and convalescent humans yield a SARS-CoV-2 antibody 695 cocktail Isolation of potent SARS-CoV-2 neutralizing antibodies and protection 701 from disease in a small animal model Shoenfeld 704 Y, Anaya JM. 2020. Convalescent plasma in Covid-19: Possible mechanisms of action 709 Effect of Convalescent Plasma Therapy on Time to Clinical Improvement in Patients With 710 Severe and Life-threatening COVID-19: A Randomized Clinical Trial Efficacy and safety of convalescent plasma for severe COVID-19 based 713 on evidence in other severe respiratory viral infections: a systematic review and meta-714 analysis Major role of 718 IgM in the neutralizing activity of convalescent plasma against SARS-CoV-2 Role of IgM and IgA Antibodies in the Neutralization of SARS-CoV-2. medRxiv 724 IgA dominates the early neutralizing antibody response to 729 SARS-CoV-2 Enhanced 733 SARS-CoV-2 neutralization by dimeric IgA Antibody potency, 738 effector function, and combinations in protection and therapy for SARS-CoV-2 infection in 739 vivo A systematic review 743 of antibody mediated immunity to coronaviruses: kinetics, correlates of protection, and 744 association with severity SARS-CoV-2 reinfection in a cohort 749 of 43,000 antibody-positive individuals followed for up to 35 weeks SARS-CoV-2 antibody signatures robustly predict diverse antiviral functions 755 relevant for convalescent plasma therapy 2021. mRNA vaccine-elicited 761 antibodies to SARS-CoV-2 and circulating variants RStudio: Integrated Development for R R: A language and environment for statistical 766 computing R Foundation for Statistical Computing RAWGraphs: A Visualisation Platform 768 to Create Open Outputs cells (IgG) Naive B−cells B−cells (IgM)